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Copyright, compared to other forms of intellectual property, is acutely and uniquely attuned
to the film and television industry. Somewhat distinctive of these industries are the numerous,
low–threshold hurdles that can significantly interfere with a copyright owner’s commercial
exploitation of their work in connection with a film or television production.
Judge Kozinski once said that “[m]ovie makers do lunch, not contracts.” While this may be
true, they also operate on representations and warranties. Indeed, a copyright owner’s ability
to represent and warrant that he controls ‘all rights’ in a work (e.g. a screenplay) is critical to
the successful commercial exploitation of a motion picture and/or television project. In such a
highly–competitive, interchangeable industry, projects are unlikely to generate significant
interest from investors, studios, production companies, and other key parties if there is even a
slight risk that an adverse legal claim in an underlying work exists. Accordingly, the purported
owner of a copyright to be exploited in connection with a film or television project must
typically make certain representations and warranties that they do in fact control all rights in
the film. If the owner cannot make these guarantees, the project is unlikely to be sold.
Unfortunately, as this is a well–known truth in the entertainment industry, it is not uncommon
for jilted parties to try and abuse this knowledge to maliciously interfere with the commercial
exploitation of a project by attempting to generate a “cloud of title” over key copyrighted
works. This is particularly dangerous, since even a legally deficient cloud of title can
significantly disrupt and impair a copyright holder’s ability to successfully market its work if it
causes investors and other essential parties to hesitate. Due to the strict, time–sensitive
nature of film and television production and release schedules, even a fleeting cloud of title
risks burning a permanent “black spot” into a project that can stop it in its tracks and disrupt it
beyond the realm of commercial feasibility. This is precisely where the MedImmune decision
can help copyright owners in the film and television industry. In fact, as illustrated by the
recent case of Jarecki v. Ohoven, there are certain unique circumstances in copyright law
where the MedImmune standard would be a welcome development.
In Jarecki, Nicholas Jarecki—writer and director of
the Sundance and commercial hit, Arbitrage, starring Richard Gere, Susan Sarandon, and Tim
Roth, and the screenplay by the same name—brought a declaratory judgment action against
Hollywood producer Michael Ohoven and his production company, Infinity Media, to establish
“(1) that Defendants [held] no copyright interests in the Screenplay or in the Film, and (2) that,

as between [Jarecki] and Defendants, the Screenplay is not a joint work and [Jarecki] is the
sole author of the work.”
Prior to the suit, Infinity Media had been in talks with Jarecki to finance and perhaps produce
the film. During this time, a third party consultant known to both parties provided “general
comments” to the screenplay. Notably, the consultant did not contribute independently–
copyrightable elements to the screenplay; and, in any event, no party expressed co–
authorship intent. Due to several disputes over financing, principal photography, and Infinity
Media’s insistence that Jarecki assign them an ownership interest in the screenplay, the parties
ended their negotiations and Jarecki obtained financing elsewhere.
After Jarecki parted ways with Infinity Media and became deeply invested in the principal
photography of the Film, he received a cease–and–desist letter from Infinity Media’s counsel,
which asserted among other things, that they would “seek immediate, emergency injunctive
and equitable relief” and “pursue all available legal and equitable claims” if Jarecki did not
cease–and–desist from engaging in all conduct related to the screenplay and/or film. As a
consequence of the letter, Jarecki and the Film faced concerned investors and were required
to renegotiate the completion bond for the Film at great expense and a higher interest
rate. Less than three weeks later, Jarecki filed for declaratory relief.
The Central District of California promptly granted Jarecki’s motion for summary judgment
because the black letter law of the Copyright Act plainly established that Jarecki was the sole
owner of copyright in the screenplay and film. Indeed, Infinity Media did not even attempt to
argue on the merits in their Opposition Brief. Additionally, and in tandem, the court dismissed
Infinity Media’s Motion for Judgment on the Pleadings, finding that the Infinity Media’s
actions created a live “case or controversy.” In holding that a “case or controversy” did in fact
exist, Judge Feess characterized Defendants’ actions as “Damoclean threat[s] . . . . [that] could
hardly more clearly threaten suit.”
Although the Central District of California decided Jarecki under the reasonable apprehension
standard, the case is nonetheless instrumental for illustrating the enormous potential benefits
of increased MedImmune deference in this copyright setting. Such disputes are all too
common in the film and television industry, and a cloud of title—whether real or imagined—
can truly destroy an otherwise promising project. In light of this danger, the “reasonable
apprehension” test arguably made Jarecki a closer call than it should have been.
MedImmune was not required to reach the right outcome in Jarecki because of the explicit
and unrestrained nature of Infinity Media’s litigious threats and acts, which buoyed the court’s
decision to grant Jarecki immediate declaratory relief. However, it is too easy to imagine
similar facts under which a valid copyright owner might not have been as victorious as Jarecki.
Fortunately, this danger can be policed with greater success under the MedImmune standard,
thanks to its elimination of the explicit “reasonable apprehension of suit” requirement in lieu

of a more permissible rule that considers the facts “under all [] circumstances” as a cohesive
whole. Accordingly, for certain copyright owners, MedImmune has the potential to be a
valuable tool to quickly dissipate nebulous, peripheral clouds of title that would otherwise risk
significantly damaging the commercial exploitation of their works. MedImmune may create a
great deal of headaches in patent and trademark, but in certain specialized areas of copyright,
it is far more likely to relieve them.
The views expressed here are exclusively of the author and do not represent agreement or
endorsement by the Cardozo Arts & Entertainment Law Journal, Benjamin N. Cardozo School
of Law, or Yeshiva University.

